Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

BACKGROUND AND AIMS: Combination atezolizumab/bevacizumab is the gold standard for first‐line treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC. METHODS: 191 consecutive patients from eight centr...

Descripción completa

Detalles Bibliográficos
Autores principales: Vithayathil, Mathew, D'Alessio, Antonio, Fulgenzi, Claudia A. M., Nishida, Naoshi, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Saeed, Anwaar, Wietharn, Brooke, Hildebrand, Hannah, Wu, Linda, Ang, Celina, Marron, Thomas U., Weinmann, Arndt, Galle, Peter R., Bettinger, Dominik, Bengsch, Bertram, Vogel, Arndt, Balcar, Lorenz, Scheiner, Bernhard, Lee, Pei‐Chang, Huang, Yi‐Hsiang, Amara, Suneetha, Muzaffar, Mahvish, Naqash, Abdul Rafeh, Cammarota, Antonella, Personeni, Nicola, Pressiani, Tiziana, Pinter, Matthias, Cortellini, Alessio, Kudo, Masatoshi, Rimassa, Lorenza, Pinato, David J., Sharma, Rohini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Liver Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825835/
https://www.ncbi.nlm.nih.gov/pubmed/35986902
http://dx.doi.org/10.1111/liv.15405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825835/
https://www.ncbi.nlm.nih.gov/pubmed/35986902
http://dx.doi.org/10.1111/liv.15405

Ejemplares similares